Clinical trials
Adverse Event clinical trials
Below are recruiting adverse event clinical trials, each written for real people, not researchers. We’re tracking 191 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07430579Recruiting
Adebrelimab with chemo for esophageal cancer
This trial tests adding adebrelimab (an immunotherapy drug) to standard chemotherapy for people with a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this combination helps shrink tumors before surgery.
JinanAges 18–80 - NCT07226791RecruitingPhase 2
Study of a drug for ventral hernia repair surgery
This trial tests a study drug (AGN-151607-DP) in adults having open surgery to repair a ventral hernia in the middle of the belly. It looks at side effects and how the hernia responds to treatment.
Riverside, CaliforniaAges 18–80 - NCT05709392Recruiting
Delayed cord clamping and early skin-to-skin for early babies
This trial studies whether waiting longer before clamping the umbilical cord and starting early skin-to-skin contact can be done safely for babies born between 30 and 35 weeks by vaginal birth. It may help support breathing, circulation, and overall early newborn care.
LinköpingAges 7 months–8 months - NCT07158814RecruitingPhase 4
Testing the safety of an RSV antibody in infants
This study checks if it is safe to delay the RSV preventive antibody shot by up to two weeks in infants who are getting their routine vaccines. Your baby will get the antibody at a second visit.
Oakland, CaliforniaAges 1 month–7 months - NCT07016022Recruiting
Heart and lung test before chest surgery helps predict risks
This study checks if a simple test of your heart and breathing before chest surgery can help predict problems after the operation. It looks at people having surgery for lung, esophagus, stomach, or chest tumors.
Ottawa, OntarioAges 18 years+ - NCT05862103Recruiting
Long-term follow-up for people after a heart attack
This trial is a long-term check-in for people who survived a heart attack and already took part in an earlier study through a 1-year follow-up. The goal is to learn what happens over time after the heart attack and how participants are doing.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06776874Recruiting
Predicting risks after an ERCP procedure
This observational study looks at patients who need an ERCP (a scope procedure for the bile ducts, liver, or pancreas). The goal is to create a score that can predict side effects after the procedure, which may help doctors better manage care.
BolognaAges 18 years+ - NCT06640010Recruiting
Studying why cancer treatments cause side effects
This study uses special cells grown in a lab to understand why some cancer treatments cause side effects. It may help researchers find ways to predict and prevent these side effects in the future.
Jacksonville, FloridaAges 18 years+ - NCT07196644RecruitingPhase 2
A study of a new drug for certain cancers with a specific gene change
This trial tests a drug called telisotuzumab adizutecan for people whose cancer has a specific genetic change called MET amplification. It may help when standard treatments are no longer working.
Beverly Hills, CaliforniaAges 12 years+ - NCT06499896RecruitingPhase 2
Donor microbiome pills for steroid-resistant skin or colon side effects
This trial tests whether a pill made from healthy donor bacteria (MTP-101-C) can help patients whose immune-related skin rash or colon inflammation did not improve with steroids. It's for people who had these side effects after receiving immunotherapy for cancer.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06485856Recruiting
Pain tracking using facial movements for non-verbal patients
This trial tests a system that measures facial movements to assess pain in patients who cannot speak or communicate verbally, such as those with a breathing tube. It may help healthcare providers better understand and manage pain in these patients.
AdanaAges 18 years+ - NCT05707949Enrolling by invitationPhase 3
Long-term safety study of atogepant for kids with migraine
This trial studies the long-term safety (side effects over time) of atogepant tablets in children and teens with migraine. It may help families understand whether the medicine is safe for longer use in ages 6 to 17.
Huntsville, AlabamaAges 6–17 - NCT07007065RecruitingPhase 3
Study of a gene therapy for wet age-related macular degeneration
This trial tests a one-time gene therapy injection for wet AMD that may reduce the need for regular eye injections. It is for people who have already responded to anti-VEGF injections but want a longer-lasting treatment.
Mesa, ArizonaAges 50 years+ - NCT07568626Recruiting
Understanding Hospital Stays After Endoscopy Procedures
This study looks at why some older patients need to stay in the hospital longer after a common digestive procedure called ERCP. Researchers want to understand the factors that affect recovery time, which may help improve care for future patients.
Xiamen, FujianAges 65 years+ - NCT07581002RecruitingPhase 2/Phase 3
New AML Treatment With Three Drug Combination Study
This study tests a new three-drug combination (pivekimab sunirine, venetoclax, and azacitidine) for newly diagnosed acute myeloid leukemia in patients who cannot tolerate intensive chemotherapy. The goal is to see if this combination is safe and effective at controlling the disease.
Phoenix, ArizonaAges 18 years+ - NCT07059845RecruitingPhase 2
Studying mirvetuximab combos for ovarian cancer
This trial tests multiple combinations of the drug mirvetuximab soravtansine with other treatments for people with ovarian cancer. It aims to see how well these combos work and what side effects they cause.
La Jolla, CaliforniaAges 18 years+ - NCT06820463RecruitingPhase 2
Study of telisotuzumab adizutecan plus chemo for metastatic colorectal cancer
This trial tests a new drug combination for people with metastatic colorectal cancer. The study includes an experimental antibody-drug conjugate (telisotuzumab adizutecan) plus standard chemotherapy and targeted therapies, to see if it works better than current options.
Duarte, CaliforniaAges 18 years+ - NCT06772623RecruitingPhase 1/Phase 2
Study of telisotuzumab adizutecan plus immunotherapy for advanced lung cancer
This trial tests a new combination treatment for people with advanced non-squamous non-small cell lung cancer who haven't received prior therapy for advanced disease and don't have specific gene changes. The treatment includes an antibody-drug conjugate (telisotuzumab adizutecan) plus an immunotherapy drug (PD-1 checkpoint inhibitor) to see if it helps shrink tumors and improve outcomes.
Phoenix, ArizonaAges 18 years+ - NCT06100744RecruitingPhase 3
Comparing two drugs for children with psoriatic arthritis
This study tests two drugs—risankizumab and adalimumab—to see which is safer and works better for children with active psoriatic arthritis. It's for kids who have not been helped enough by standard disease-modifying drugs.
Little Rock, ArkansasAges 5–17 - NCT06568939RecruitingPhase 2
Study of telisotuzumab vedotin for non-squamous lung cancer
This trial tests a drug called telisotuzumab vedotin (ABBV-399) given through a vein to people with a specific type of advanced lung cancer (non-squamous non-small cell lung cancer) that has a high level of a protein called c-Met. The study aims to see how the drug affects the body and helps control the cancer.
Chandler, ArizonaAges 18 years+ - NCT06892522RecruitingPhase 1/Phase 2
T cell therapies for multiple myeloma
This trial tests new antibody treatments for multiple myeloma, given alone or with other drugs. It aims to see if they can control the disease and what side effects might occur.
Duarte, CaliforniaAges 18 years+ - NCT05609630RecruitingPhase 3
Testing two medicines for active systemic juvenile arthritis
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
Phoenix, ArizonaAges 1–17 - NCT06822738RecruitingPhase 3
Study of XEN63 gel stent for glaucoma patients
This trial tests a new gel stent (XEN63) to lower eye pressure in adults with glaucoma. It compares two ways of putting the stent in the eye, and may help people who have not had success with other treatments.
Glendale, ArizonaAges 45 years+ - NCT06230341Recruiting
Safety incidents in primary care teams
This study looks at how patient safety problems happen in coordinated primary care teams (called MSPs) in the Pays de la Loire region of France. It aims to understand and improve safety for patients and staff.
Nantes, FranceAges Any age
Hear when a new Adverse Event trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for adverse event?
- Yes. Clin2 currently lists 191 recruiting adverse event studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a adverse event trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a adverse event trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.